PT - JOURNAL ARTICLE AU - Nazzicone, Kristina AU - Kirkpatrick, Ryan H. AU - Biorac, Aleksandar AU - Froentjes, Anneke R. AU - Molin, Sonja AU - Simpson, Sarah TI - Prevalence of ocular manifestations in cutaneous rosacea: Protocol for a systematic review and meta-analysis AID - 10.1101/2024.01.31.24301198 DP - 2024 Jan 01 TA - medRxiv PG - 2024.01.31.24301198 4099 - http://medrxiv.org/content/early/2024/02/01/2024.01.31.24301198.short 4100 - http://medrxiv.org/content/early/2024/02/01/2024.01.31.24301198.full AB - Introduction: Rosacea is a chronic inflammatory skin condition with concomitant ocular manifestations and neurogenic symptoms. Ocular rosacea poses a particular diagnostic challenge as its signs and symptoms often overlap with other ocular pathologies. Cutaneous and ocular rosacea present together in approximately 21-50% of patients, yet a solid understanding of comorbid ocular and cutaneous symptoms is lacking. Therefore, the present paper outlines a protocol for a systematic review and meta-analysis to describe and quantify the prevalence of ocular rosacea in cutaneous rosacea and each of its subtypes. Methods: This study will follow Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and be conducted using the systematic review software, Covidence. To determine inclusion, screening will occur at two levels (title and abstract-only followed by full-text) and will be completed separately by two authors. Primary research studies on ocular rosacea in adult cutaneous rosacea published in all languages and geographic regions until November 2023 will be reviewed for inclusion. Data pertaining to overall prevalence of ocular rosacea across and within cutaneous rosacea subtypes, mean age, sex, gender, ethnicity, socioeconomic status, time to diagnosis, time to treatment, and prevalence of comorbid conditions will be extracted. For each included study, the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) framework will be applied to assess study quality. Conclusion: To the authors’ knowledge, this will be the first systematic review and meta-analysis comparing the prevalence of ocular rosacea in the various cutaneous subtypes in an adult population. By addressing this knowledge gap, this study aims to provide clear and easily interpretable data to aid in the early diagnosis and treatment of ocular rosacea. This study is registered in the International Prospective Register of Systematic Reviews (PROSPERO ID# CRD42023475026).Key Message Protocol for a systematic review and meta-analysis investigating the prevalence of ocular manifestations in adult rosaceaCompeting Interest StatementThe authors have declared no competing interest.Funding StatementRHK is funded by a Vanier Canada Graduate Scholarship from the Canadian Institutes of Health Research (CIHR) and the Canadian Federation of University Women's 1989 Ecole Polytechnique Commemorative Award.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study describes the protocol for a systematic review and meta-analysis that will collect data from already published and de-identified human research. These studies are accessible from Embase, MEDLINE, PubMed, Web of Science, ProQuest, and Cochrane Central Register of Controlled Trials (CENTRAL)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData sharing is not applicable to this study as no new data will be created or analyzed.